Growth Metrics

Trinity Biotech (TRIB) Return on Equity (2021 - 2022)

Trinity Biotech recorded quarterly Return on Equity of 0.2% in Q4 2022, down 500.84% quarter-over-quarter from 0.03% in Q3 2022, and down 34.0% year-over-year from 0.3% in Q4 2021.

Trinity Biotech's Return on Equity history runs 2 years deep, the most recent figure standing at 0.2% for Q4 2022.

  • In Q4 2022, Return on Equity fell 34.0% year-over-year to 0.2%; the TTM figure through Dec 2022 stood at 0.2% (down 34.0% YoY), while the FY2025 annual figure was 0.01%, up 1.0% from the prior year.
  • Return on Equity came in at 0.2% for Q4 2022 at Trinity Biotech, down from 0.03% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 1.09% in Q3 2021 to a low of 0.83% in Q2 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROE (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 0.00%
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn 0.00%
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn 0.00%
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn 0.00%
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn 0.00%
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn 0.00%
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn 0.00%
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn -
10 Trinity Biotech 28,000.00 -5.11 Mn - -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2022 -0.20%
Sep 30, 2022 -0.03%
Jun 30, 2022 -0.05%
Mar 31, 2022 0.04%
Dec 31, 2021 0.14%
Sep 30, 2021 1.09%
Jun 30, 2021 -0.83%
Mar 31, 2021 -0.41%